Events & Promotions
|
|
GMAT Club Daily Prep
Thank you for using the timer - this advanced tool can estimate your performance and suggest more practice questions. We have subscribed you to Daily Prep Questions via email.
Customized
for You
Track
Your Progress
Practice
Pays
Not interested in getting valuable practice questions and articles delivered to your email? No problem, unsubscribe here.
Apr 2601:30 AM EDT
-02:30 AM EDT
Learn how Keshav, a Chartered Accountant, scored an impressive 705 on GMAT in just 30 days with GMATWhiz's expert guidance. In this video, he shares preparation tips and strategies that worked for him, including the mock, time management, and more.
Apr 2512:30 AM EDT
-01:30 AM EDT
At one point, she believed GMAT wasn’t for her. After scoring 595, self-doubt crept in and she questioned her potential. But instead of quitting, she made the right strategic changes. The result? A remarkable comeback to 695. Check out how Saakshi did it.
Apr 2610:00 AM EDT
-11:00 AM EDT
The Target Test Prep course represents a quantum leap forward in GMAT preparation, a radical reinterpretation of the way that students should study. Try before you buy with a 5-day, full-access trial of the course for FREE!
Apr 2711:00 AM EDT
-12:00 PM EDT
Prefer video-based learning? The Target Test Prep OnDemand course is a one-of-a-kind video masterclass featuring 400 hours of lecture-style teaching by Scott Woodbury-Stewart, founder of Target Test Prep and one of the most accomplished GMAT instructors
Apr 2808:00 AM PDT
-11:00 AM PDT
Whether you are just beginning your MBA journey or fine-tuning your path to a 700+ score, GMAT Day is designed to give you a competitive edge.
May 0111:00 AM PDT
-12:00 PM PDT
Free- full-length test + 15 concept videos + 150+ short videos + study plan!
18 Feb 2020, 04:48
Kudos
Bookmarks
C
Be sure to select an answer first to save it in the Error Log before revealing the correct answer (OA)!
Difficulty:
35%
(medium)
Question Stats:
76% (02:07) correct
24%
(02:12)
wrong
based on 291
sessions
History
Date
Time
Result
Not Attempted Yet
Two alternative drugs are available to prevent blood clots from developing after a heart attack. According to two major studies, drug Y does this no more effectively than the more expensive drug Z, but drug Z is either no more or only slightly more effective than drug Y. Drug Z’s manufacturer, which has engaged in questionable marketing practices such as offering stock options to doctors who participate in clinical trials of drug Z, does not contest the results of the studies but claims that they do not reveal drug Z’s advantages. However, since drug Z does not clearly treat the problem more effectively than drug Y, there is no established medical reason for doctors to use drug Z rather than drug Y on their heart-attack victims.
A major flaw in the argument is that the argument
(A) does not consider drugs or treatments other than drug Y and Z that may be used to prevent blood clotting in heart-attack patients
(B) neglects to compare the marketing practices of drug Y’s manufacturer with those of drug Z’s manufacturer
(C) fails to recognize that there may be medical criteria relevant to the choice between the two drugs other than their effectiveness as a treatment
(D) assumes without proof that the two drugs are similar in their effectiveness as treatments because they are similar in their chemical composition
(E) confuses economic reasons for selecting a treatment with medical reasons
A major flaw in the argument is that the argument
(A) does not consider drugs or treatments other than drug Y and Z that may be used to prevent blood clotting in heart-attack patients
(B) neglects to compare the marketing practices of drug Y’s manufacturer with those of drug Z’s manufacturer
(C) fails to recognize that there may be medical criteria relevant to the choice between the two drugs other than their effectiveness as a treatment
(D) assumes without proof that the two drugs are similar in their effectiveness as treatments because they are similar in their chemical composition
(E) confuses economic reasons for selecting a treatment with medical reasons
22 Mar 2020, 19:30
Kudos
Bookmarks
background: Z is more expensive but slightly more effective than Y.And Z's Manufacturer said Z has other advantages,not revealed by studies yet;
Main Premise :since(premise Indicator keyword) drug Z does not clearly treat the problem more effectively than drug Y;
Conclusion : there is no established medical reason for doctors to use drug Z rather than drug Y on their heart-attack victims.
Prethink: Effectiveness is the only criteria? There cud be other medical criteria,drugs' side-effects?
A major flaw in the argument is that the argument : POE
(A) does not consider drugs or treatments other than drug Y and Z that may be used to prevent blood clotting in heart-attack patients. Comparison is between Y & Z. So other drug is out of scope any way.
(B) neglects to compare the marketing practices of drug Y’s manufacturer with those of drug Z’s manufacturer. :not a medical Reason;
(C) fails to recognize that there may be medical criteria relevant to the choice between the two drugs other than their effectiveness as a treatment : Correct
(D) assumes without proof that the two drugs are similar in their effectiveness as treatments because they are similar in their chemical composition: Chemical composition is not given Oout of Scope
(E) confuses economic reasons for selecting a treatment with medical reasons; Economic reasons are not in main Premise, but effectiveness .
Main Premise :since(premise Indicator keyword) drug Z does not clearly treat the problem more effectively than drug Y;
Conclusion : there is no established medical reason for doctors to use drug Z rather than drug Y on their heart-attack victims.
Prethink: Effectiveness is the only criteria? There cud be other medical criteria,drugs' side-effects?
A major flaw in the argument is that the argument : POE
(A) does not consider drugs or treatments other than drug Y and Z that may be used to prevent blood clotting in heart-attack patients. Comparison is between Y & Z. So other drug is out of scope any way.
(B) neglects to compare the marketing practices of drug Y’s manufacturer with those of drug Z’s manufacturer. :not a medical Reason;
(C) fails to recognize that there may be medical criteria relevant to the choice between the two drugs other than their effectiveness as a treatment : Correct
(D) assumes without proof that the two drugs are similar in their effectiveness as treatments because they are similar in their chemical composition: Chemical composition is not given Oout of Scope
(E) confuses economic reasons for selecting a treatment with medical reasons; Economic reasons are not in main Premise, but effectiveness .
31 Aug 2024, 09:12
Kudos
Bookmarks
Two alternative drugs are available to prevent blood clots from developing after a heart attack. According to two major studies, drug Y does this no more effectively than the more expensive drug Z, but drug Z is either no more or only slightly more effective than drug Y. Drug Z’s manufacturer, which has engaged in questionable marketing practices such as offering stock options to doctors who participate in clinical trials of drug Z, does not contest the results of the studies but claims that they do not reveal drug Z’s advantages. However, since drug Z does not clearly treat the problem more effectively than drug Y, there is no established medical reason for doctors to use drug Z rather than drug Y on their heart-attack victims.
A major flaw in the argument is that the argument
(A) does not consider drugs or treatments other than drug Y and Z that may be used to prevent blood clotting in heart-attack patients - WRONG. That may shift the scope so it can't be a flaw.
(B) neglects to compare the marketing practices of drug Y’s manufacturer with those of drug Z’s manufacturer - WRONG. That's irrelevant.
(C) fails to recognize that there may be medical criteria relevant to the choice between the two drugs other than their effectiveness as a treatment - CORRECT. Why major studies considered the two is not answered by the passage.
(D) assumes without proof that the two drugs are similar in their effectiveness as treatments because they are similar in their chemical composition - WRONG. A subtle difference between the two is already mentioned and also chemical composition is not discussed.
(E) confuses economic reasons for selecting a treatment with medical reasons - WRONG. The last sentence clearly states that it was about effectiveness of the drug medically.
Answer C.
A major flaw in the argument is that the argument
(A) does not consider drugs or treatments other than drug Y and Z that may be used to prevent blood clotting in heart-attack patients - WRONG. That may shift the scope so it can't be a flaw.
(B) neglects to compare the marketing practices of drug Y’s manufacturer with those of drug Z’s manufacturer - WRONG. That's irrelevant.
(C) fails to recognize that there may be medical criteria relevant to the choice between the two drugs other than their effectiveness as a treatment - CORRECT. Why major studies considered the two is not answered by the passage.
(D) assumes without proof that the two drugs are similar in their effectiveness as treatments because they are similar in their chemical composition - WRONG. A subtle difference between the two is already mentioned and also chemical composition is not discussed.
(E) confuses economic reasons for selecting a treatment with medical reasons - WRONG. The last sentence clearly states that it was about effectiveness of the drug medically.
Answer C.
